Unknown

Dataset Information

0

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.


ABSTRACT: BACKGROUND:Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF. METHODS AND RESULTS:These peptides are direct thrombin inhibitors prolonging the thrombin clotting time, activated partial thromboplastin time, and prothrombin time at >or=0.78, 1.6, and 1.6 microm, respectively. They competitively inhibit alpha-thrombin-induced cleavage of a chromogenic substrate at 4.4-8.2 microm. They do not significantly inhibit plasma kallikrein, factor (F) XIIa, FXIa, FIXa, FVIIa-TF, FXa, plasmin or cathepsin G. One form, FM19 [rOicPaF(p-Me)], blocks alpha-thrombin-induced calcium flux in fibroblasts with an IC(50) of 6.9 +/- 1.2 microm. FM19 achieved 100% inhibition of threshold alpha- or gamma-thrombin-induced platelet aggregation at 8.4 +/- 4.7 microm and 16 +/- 4 microm, respectively. The crystal structure of thrombin in complex with FM19 shows that the N-terminal D-Arg retrobinds into the S1 pocket, its second residue Oic interacts with His-57, Tyr-60a and Trp-60d, and its C-terminal p-methyl Phe engages thrombin's aryl binding site composed of Ile-174, Trp-215, and Leu-99. When administered intraperitoneal, intraduodenal, or orally to mice, FM19 prolongs thrombin clotting times and delays carotid artery thrombosis. CONCLUSION:FM19, a low affinity reversible direct thrombin inhibitor, might be useful as an add-on agent to address an unmet need in platelet inhibition in acute coronary syndromes in diabetics and others who with all current antiplatelet therapy still have reactive platelets.

SUBMITTER: Nieman MT 

PROVIDER: S-EPMC2652574 | biostudies-literature | 2008 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Nieman M T MT   Burke F F   Warnock M M   Zhou Y Y   Sweigart J J   Chen A A   Ricketts D D   Lucchesi B R BR   Chen Z Z   Di Cera E E   Hilfinger J J   Kim J S JS   Mosberg H I HI   Schmaier A H AH  

Journal of thrombosis and haemostasis : JTH 20080225 5


<h4>Background</h4>Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF.<h4>Methods and results</h4>These peptides are direct thrombin inhibitors prolonging the thrombin clotting time, activated partial thromboplastin time, and prothrombin time at >or=0.78, 1.6, and 1.6 microm, respectively. They competitively inhibit alpha-thrombin-ind  ...[more]

Similar Datasets

| S-EPMC3195735 | biostudies-literature
| S-EPMC6072017 | biostudies-literature
| S-EPMC9036856 | biostudies-literature
| S-EPMC7936662 | biostudies-literature
| S-EPMC8772750 | biostudies-literature
| S-EPMC8617063 | biostudies-literature
| S-EPMC7762001 | biostudies-literature
| S-EPMC5012373 | biostudies-literature
| S-EPMC7135739 | biostudies-literature
| S-EPMC8358470 | biostudies-literature